Serna Bio
YC W21Ontario, US · Founded 2021 · 5 employees · 4 known investors
Find your way into Serna Bio
915 people in our graph share verified history with the Serna Bio team — schools, employers, funds. One of them is your warm intro.
Laviva Mazharunlockedknows Dr. Rabia Khan · together at McGill University (overlapped)
×9knows the team · via Y Combinator
×2knows the team · via Concordia University
Serna builds a platform to unlock the transcriptome as a drug target for drug discovery. The company integrates technology and biology to change drug discovery processes.
Also known as Ladder Therapeutics (LTX)
AI & Machine LearningBiotechDeep TechHealthtechDrug discoveryUnited States of AmericaAmerica / CanadaFully Remote
Founders & leadership· Y Combinator alumni (W21)
Serna Bio was founded in 2021 by Rabia Khan.
RK
Rabia Khanin𝕏Founder/CEORabia Khan previously led machine learning efforts at Sensyne Health and worked at BenevolentAI. She now focuses on small-molecule RNA therapeutics.
Investors · 4
Founder mafia
2 people who came through Serna Bio went on to found or lead other companies.
Competitors · 10
by search overlap
Sionnatx29 shared keywordsSionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs. It is advancing a portfolio of NBD1 stabilizers and complementary CFTR modulators intended to be used in combination to normalize CFTR function in CF patients.
Syrna Therapeutics23 shared keywordsSyrna Therapeutics is a biotech company developing small-molecule covalent translation inhibitors that bind and modify structured domains in the mRNA of disease-causing proteins to block their expression. It uses a 3D structure-guided drug discovery platform, with lead programs in immunology and neurodegeneration and a broader pipeline spanning metabolic disease and oncology.
Sirnaomics20 shared keywordsSirnaomics is an RNA therapeutics company developing RNA interference (RNAi) drugs using its proprietary PNP (Peptide Nanoparticle) delivery platform for extra-hepatic delivery and its GalAHead technology for controlling therapeutic duration. Its pipeline spans oncology, regenerative and aesthetic medicine, and cardiovascular and metabolic diseases.
Ronatherapeutics19 shared keywordsRona Therapeutics develops siRNA-based therapeutics using its GAIA platform to target metabolic and cardiovascular conditions including hypertriglyceridemia, obesity, ASCVD, and MASH. Its pipeline includes APOC3, INHBE, PCSK9-Lp(a), and angiotensinogen-targeting candidates for patients with cardiovascular and metabolic diseases.
Switch Therapeutics19 shared keywordsSwitch Therapeutics develops RNA interference (RNAi) therapeutic applications targeting central nervous system diseases, leveraging research from Caltech, Harvard Medical School, and City of Hope.
Silence Therapeutics17 shared keywordsSilence Therapeutics is a biotechnology company that discovers and develops short interfering RNA (siRNA) molecules designed to reduce the production of disease-associated proteins through the natural mechanism of RNA interference, with its proprietary mRNAi GOLD platform targeting specific genes in the liver for rare and common diseases.
Starnatx16 shared keywordsStarna Therapeutics develops RNA-based therapeutic drugs focused on hepatic and extrahepatic targeted delivery technology. The company has built a proprietary platform of cationic lipids and lipid nanoparticles (LNPs) to achieve organ-specific delivery and is advancing clinical-stage mRNA vaccine and mRNA therapeutic candidates.
Day One Biopharmaceuticals16 shared keywordsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.
Siriusrna15 shared keywordsSirius Therapeutics is a biopharmaceutical company developing siRNA-based therapeutics, including work in the anti-coagulant therapeutic area. It focuses on drug discovery and clinical development of RNA-based medicines.
ロゴマーク：AIRNA14 shared keywordsAIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA. The company targets diseases where the underlying genetic mechanism is well-established and difficult to address with existing therapeutic approaches.
Companies competing with Serna Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Serna Bio do?
- Serna builds a platform to unlock the transcriptome as a drug target for drug discovery. The company integrates technology and biology to change drug discovery processes.
- Who founded Serna Bio?
- Serna Bio was founded by Rabia Khan in 2021.
- Who are Serna Bio's investors?
- Serna Bio's investors include Backed, Hummingbird Ventures, Lifeforce Capital, Y Combinator.
- Where is Serna Bio headquartered?
- Serna Bio is headquartered in Ontario, US.